{
  "openalex_id": "W1604083967",
  "doi": "https://doi.org/10.1111/jphp.12072",
  "title": "Carfilzomib: a novel agent for multiple myeloma",
  "abstract": "Abstract Objectives Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma (MM). This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and administration of carfilzomib, and its role in treating MM patients. Key findings Carfilzomib is a selective proteasome inhibitor that differs structurally and mechanistically from bortezomib. In patients' whole-blood and peripheral-blood mononuclear cells, carfilzomib inhibited proteasomal and immunoproteasomal activity by 70–80%. Approved carfilzomib dosing is based on body surface area, and is given on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle (20 mg/m2 in cycle 1; 27 mg/m2 in cycle 2+). Premedication with dexamethasone and adequate hydration are recommended to reduce the risk of adverse events. The median t1/2 of carfilzomib is short (0.29–0.48 h), with no accumulation detected between doses. In clinical studies in relapsed and refractory MM. and in combinations in newly diagnosed MM, single-agent carfilzomib demonstrated significant durable activity, good tolerability and a favourable safety profile, supporting its extended use. Conclusions Carfilzomib represents an important addition to the treatment armamentarium for patients with relapsed and/or refractory MM, and studies are underway evaluating the role of single-agent carfilzomib in additional clinical settings as well as in different combinations.",
  "authors": [
    {
      "display_name": "Kimberly Redic",
      "id": "A5014458772",
      "orcid": null,
      "institutions": [
        {
          "id": "I27837315",
          "display_name": "University of Michigan",
          "country_code": "US",
          "type": "funder"
        },
        {
          "id": "I4210114445",
          "display_name": "Michigan Medicine",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": true,
      "raw_author_name": "Kimberly Redic"
    }
  ],
  "publication_year": 2013,
  "publication_date": "2013-04-24",
  "type": "review",
  "cited_by_count": 37,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S118304455",
    "display_name": "Journal of Pharmacy and Pharmacology",
    "issn_l": "0022-3573",
    "issn": [
      "0022-3573",
      "2042-7158"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310311648"
  },
  "volume": "65",
  "issue": "8",
  "first_page": "1095",
  "last_page": "1106",
  "open_access": {
    "is_oa": true,
    "oa_status": "bronze",
    "oa_url": "https://academic.oup.com/jpp/article-pdf/65/8/1095/36387114/jphp12072.pdf",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C2780108899",
      "display_name": "Carfilzomib",
      "level": 4,
      "score": 0.99732673
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.78076816
    },
    {
      "id": "C2778367456",
      "display_name": "Proteasome inhibitor",
      "level": 3,
      "score": 0.6315275
    },
    {
      "id": "C2778375690",
      "display_name": "Tolerability",
      "level": 3,
      "score": 0.6216102
    },
    {
      "id": "C2777288759",
      "display_name": "Dosing",
      "level": 2,
      "score": 0.60700816
    },
    {
      "id": "C197934379",
      "display_name": "Adverse effect",
      "level": 2,
      "score": 0.598507
    },
    {
      "id": "C98274493",
      "display_name": "Pharmacology",
      "level": 1,
      "score": 0.5863623
    },
    {
      "id": "C2777478702",
      "display_name": "Bortezomib",
      "level": 3,
      "score": 0.56714267
    },
    {
      "id": "C112705442",
      "display_name": "Pharmacokinetics",
      "level": 2,
      "score": 0.5446737
    },
    {
      "id": "C2776364478",
      "display_name": "Multiple myeloma",
      "level": 2,
      "score": 0.5230792
    },
    {
      "id": "C142424586",
      "display_name": "Refractory (planetary science)",
      "level": 2,
      "score": 0.47207475
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.37628198
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.30192816
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.06313339
    },
    {
      "id": "C87355193",
      "display_name": "Astrobiology",
      "level": 1,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T10649",
      "display_name": "Multiple Myeloma Research and Treatments",
      "score": 1.0
    },
    {
      "id": "T12534",
      "display_name": "Protein Degradation and Inhibitors",
      "score": 0.9959
    },
    {
      "id": "T11041",
      "display_name": "Ubiquitin and proteasome pathways",
      "score": 0.9848
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1111/jphp.12072",
  "pdf_url": "https://academic.oup.com/jpp/article-pdf/65/8/1095/36387114/jphp12072.pdf",
  "retrieved_date": "2025-07-30T14:57:12.928888",
  "source_database": "OpenAlex"
}